➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Harvard Business School

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

XENAZINE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Xenazine patents expire, and what generic alternatives are available?

Xenazine is a drug marketed by Valeant Pharms North and is included in one NDA.

The generic ingredient in XENAZINE is tetrabenazine. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the tetrabenazine profile page.

US ANDA Litigation and Generic Entry Outlook for Xenazine

A generic version of XENAZINE was approved as tetrabenazine by SUN PHARM on August 17th, 2015.

  Start Trial

Drug patent expirations by year for XENAZINE
Drug Prices for XENAZINE

See drug prices for XENAZINE

Recent Clinical Trials for XENAZINE

Identify potential brand extensions & 505(b)(2) entrants

Adeptio PharmaceuticalsPhase 1
Kirk A. FreyPhase 1
Dr. Reddy's Laboratories LimitedPhase 1

See all XENAZINE clinical trials

US Patents and Regulatory Information for XENAZINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms North XENAZINE tetrabenazine TABLET;ORAL 021894-001 Aug 15, 2008 AB RX Yes No   Start Trial   Start Trial   Start Trial
Valeant Pharms North XENAZINE tetrabenazine TABLET;ORAL 021894-002 Aug 15, 2008 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.